Total Cholesterol Concentration Predicts the Effect of Plasmapheresis on Hypertriglyceridemic Acute Pancreatitis

zhuchen
The First Affiliated Hospital of Xiamen University

xiaolong Huang
The First Affiliated Hospital of Xiamen University

na Han
BloodCenter of Xiamen

Yanxia Guo
The First Affiliated Hospital of Xiamen University

Jing Chen
The First Affiliated Hospital of Xiamen University

yaogui Ning
The First Affiliated Hospital of Xiamen University

minwei zhang (zmwicu2019@sina.com)
the first affiliated hospital of Xiamen University

Research

Keywords: total cholesterol, plasmapheresis, effectiveness, hypertriglyceridemia, acute pancreatitis

DOI: https://doi.org/10.21203/rs.3.rs-29813/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The clinical efficacy of plasmapheresis (PP) in patients with hypertriglyceridemic acute pancreatitis (HLAP) might be affected by total cholesterol (TC). The objective of this study is to determine the relationship of TC and the Triglyceride (TG)-lowering effect in patients on either non-PP or PP therapy.

Methods

Patients were categorized into high total cholesterol (HTC)/low total cholesterol (LTC) groups based on TC level of 12.4 mmol/l. The primary outcome was TG reduction to below 500 mg/dl within 48 hours. Linear mixed-effect model and logistic regression analyses were used to assess the association of TC and different therapy groups on TG-lowering efficacy.

Results

Compared with LTC group, patients with HTC showed more severe imaging manifestations (p<0.001) and higher APACH scores (p=0.036). Deaths occurred only in HTC groups. Significant interaction of time sequence with the 2 TGs-lowering therapy groups on TG level was only found in HTC group (p < 0.001). In patients with elevated TC level, primary outcome occurred in 66.67% of patients in the PP group, and 27.91% in the non-PP group. After adjustment for age, gender, CT grade and APACH II score, the odd ratio remain significant (OR 5.47, 95% confidence interval [CI] 1.84-16.25, p = 0.002). Furthermore, in patients with lower TC level, primary outcome occurred in 81.25% of patients in the PP group, and 62.30% in the non-PP group (adjusted OR 2.05; 95% CI 0.45–9.40; p = 0.353).

Conclusions:

TC could be a potential biomarker to predict the effects of TG-lowering therapy in patients with HLAP.

Introduction

Acute pancreatitis (AP) is a common and potentially life-threatening disease in the clinical setting[1]. After gallstones (up to 60%) and alcohol (30%), hypertriglyceridemia is the third most common cause of AP, accounting for nearly 10% of all cases[2]. The incidence of hypertriglyceridemic acute pancreatitis (HLAP) is gradually increasing[3, 4], and its associated mortality can exceed 30%[5].

There is no internationally recognized treatment for HLAP. Strict restrictions regarding oral fasting, fluid resuscitation and analgesia are basic treatment measures for HLAP. In addition to traditional treatments, plasmapheresis (PP) have also been recommended for the treatment of HLAP[6, 7].

At present, the clinical efficacy of PP for patients with HLAP is still unclear and controversial. PP can remove triglycerides (TGs) and chylomicron from circulation drastically within hours[8]. However, many
studies have found that PP does not improve mortality rates among patients with HLAP[9, 10]. Moreover, a recent retrospective study found that PP therapy had no additional TG-lowering effects in patients with HLAP[11]. In addition, PP requires special treatment equipment, is expensive, and involves some risks, such as plasma allergy, bleeding and infection[12]. The vast heterogeneity of the underlying clinical scenarios of patients with HLAP partly leads to TG-lowering treatment failure. Identifying the patients who are more suitable for PP is of significant importance, but few relevant studies have been published. Total cholesterol (TC) can act as an early predictor of persistent organ failure and mortality in patients with AP [13, 14]. Additionally, TC are favorable predictors of the development of severe acute pancreatitis (SAP) in patients with AP [15]. Accordingly, we propose that TC levels might be useful to predict patients’ response to TG-lowering therapy.

Materials And Methods

This retrospective study was approved by the institutional review board of the first affiliated hospital of Xiamen University.

Patients

Between January 2013 and December 2018, 1772 patients were diagnosed with pancreatitis and received treatment at the first affiliated hospital of Xiamen University. (Xiamen, China). A total of 150 patients, 46 patients treated with PP and 104 patients did not, were diagnosed with HLAP and included in this retrospective comparative study. HLAP was diagnosed using the Atlanta Classification criteria[16]. The inclusion criteria were as follows: 1. TGs > 1000 mg/dl; 2. the occurrence of two in the following three factors: typical abdominal pain, pancreatic enzymes exceeding the normal upper limit by more than 3 times, and radiological findings of AP; 3. age of 18 years or older. We excluded pregnant women with HLAP and patients with other causative conditions, such as gall stones, trauma or neoplasm.

Treatment

The initial treatment of HLAP, as with other causes of pancreatitis, includes intestinal rest, fasting, intravenous fluids and pain relief. PP was performed as soon as possible in patients who agreed to receive the treatment. The PP sessions were performed using the Aquarius system (Edwards Lifesciences LLC, One Edwards Way, Irvine, USA) and the Plasmaflo TPE op-08w filter (Asahi KASEI Medical Co., Ltd, Yurakucho, Chiyoda-ku, Tokyo). In general, approximately 3 liters of plasma were exchanged at a time, and the treatments lasted approximately 3 hours. During PP, heparin (500 U/h) was continuously pumped before the filter, and calcium (1 g/ h) was added after the filter. PP was performed daily until TG levels were below 1000 mg/dL[2].

Outcome
The primary efficacy outcome was TGs $< 500$ mg/dl within 48 hours of admission[17]. The secondary efficacy outcome included the change in serum TG concentrations within 72 hours of admission.

**Data Collection**

Demographic, clinical, and laboratory data were collected on the day of admission. Demographic data included age, sex and body mass index (BMI). Clinical variables included hypertension, diabetes mellitus and diabetic ketosis, hyperuricemia and medical history of pancreatitis. Baseline levels of TC, HDL-C, LDL-C, prealbumin, albumin, serum calcium, C-reactive protein, amylase and lipase were also collected within 24 hours of admission. The time course of serum TG concentration (at baseline, 24 hours, 48 hours and 72 hours) was involved in the results analysis. The severity of HLAP was assessed by the Ranson score, the APACHE II score, the Balthazar CT grade and organ function[18]. We simultaneously collected data regarding medical treatment for hypertriglyceridemia (insulin and heparin), complications or comorbidities of HLAP, length of hospitalization, hospital charges, and mortality at 28 days and 90 days.

**Statistical analysis**

Statistical analyses were performed using R for Windows (version 3.4.2, http://www.r-project.org/). The data are presented as the median (interquartile range) or number (%). Patients were categorized into high total cholesterol (HTC) / low total cholesterol (LTC) groups based on a TC level of 12.4 mmol/l (2 times the ‘high’ limit of total cholesterol based on the recommendations of the National Heart, Lung, and Blood Institute (NHLBI) of the United States[19]). Categorical variables were compared by chi-square/Fisher’s exact tests. Because of skewed distribution, continuous variables were compared by the Mann-Whitney U test. For LTC and HTC group, the difference between PP and non-PP therapy in the rates of TG $< 500$ mg/dl within 48 hours of admission was analyzed by using univariate and multivariate logistic regression analyses. We included predictors with a p value $< 0.1$ from univariate analysis into the backward stepwise multivariate regression with the Akaike Information Criterion (AIC). Treatment group (PP group and non-PP group)-time sequence interactions were assessed using the linear mixed-effect model according to repeated measures of TGs. After classifying the patients into four groups based on TC and TG-lowering therapy, we used Fisher’s exact tests and Kruskal–Wallis test to compare categorical and continuous variables. P value were adjusted by Bonferroni correction for multiple comparisons among the defined groups. A 2-sided p value of less than 0.05 was considered to indicate statistical significance.

**Results**

**Patient characteristics**
A total of 150 patients were included in this study. Forty-six patients received therapeutic PP, and 104 patients did not. The baseline clinical characteristics are listed in Table 1. The median age was 38 years. Most of the patients were male (78.67%) and had a high BMI (median 26.15; IQR 24.20–28.30). 39.33% of the patients had previous pancreatitis. The median plasma levels of TGs and TC were 1760.2 mg/dl and 12.28 mmol/l, respectively. More than half (51.33%) of the patients showed more fluid leakage on imaging (Balthazar CT grade: D/E). Organ dysfunction occurred in 20% of all patients. 84 (56%) patients were treated with insulin/heparin for reducing plasma TGs.
Table 1
Baseline clinical characteristics

|                | All (n = 150) | LTC group (Cholesterol ≤ 12.40 mmol/L, n = 77) | HTC group (Cholesterol > 12.40 mmol/L, n = 73) | P    |
|----------------|---------------|------------------------------------------------|-------------------------------------------------|------|
| Baseline characteristics |               |                                                |                                                 |      |
| Age, years      | 38.00 (31.00–44.00) | 36.00 (31.00–43.00) | 40.00 (33.00–45.00) | 0.047 |
| Male            | 118 (78.67%)   | 66 (85.71%)          | 52 (71.23%)          | 0.049 |
| BMI, kg/m²      | 26.15 (24.20–28.30) | 26.00 (24.80–28.40) | 26.40 (24.20–28.30) | 0.880 |
| Hypertension    | 23 (15.33%)    | 10 (12.99%)          | 13 (17.80%)          | 0.553 |
| Diabetes        | 44 (29.33%)    | 20 (25.97%)          | 24 (32.88%)          | 0.454 |
| History of pancreatitis | 59 (39.33%) | 33 (45.21%)          | 25 (34.25%)          | 0.282 |
| TG, mg/dL       | 1760.20 (1187.60–2534.30) | 1599.10 (1140.70–1981.40) | 2224.80 (1351.30–3291.20) | <0.001 |
| TC, mmol/L      | 12.28 (8.83–15.96) |                                                |                                                 |      |
| HDL-C, mmol/L   | 0.97 (0.59–2.86) | 0.97 (0.61–2.37)     | 0.93 (0.58–4.23)     | 0.347 |
| LDL-C, mmol/L   | 2.86 (1.55–5.30) | 1.91 (1.18–3.31)     | 4.50 (2.13–7.23)     | <0.001 |
| Ca, mmol/L      | 2.17 (1.98–2.48) | 2.24 (2.05–2.48)     | 2.11 (1.95–2.59)     | 0.183 |
| Amylase, U/L    | 202.00 (108.20–391.80) | 246.00 (110.00–373.00) | 182.00 (84.00–396.00) | 0.330 |
| Lipase, U/L     | 627.80 (290.30–1513.20) | 588.00 (288.10–1496.00) | 637.00 (297.60–1592.00) | 0.867 |
| Severity of hypertriglyceridemic pancreatitis |               |                                                |                                                 |      |
| Balthazar CT grade |               |                                                |                                                 |      |
| <D              | 73 (48.67%)    | 48 (62.33%)          | 25 (34.25%)          |      |
| ≥D              | 77 (51.33%)    | 29 (37.66%)          | 48 (65.75%)          |      |
| Organ function  |               |                                                |                                                 | 0.111 |

BMI: body mass index; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Ca: calcium.
|                | All (n = 150) | LTC group (Cholesterol ≤ 12.40 mmol/L, n = 77) | HTC group (Cholesterol > 12.40 mmol/L, n = 73) | P  |
|----------------|--------------|-----------------------------------------------|-----------------------------------------------|----|
| NO             | 120 (80.00%) | 66 (85.71%)                                   | 54 (73.97%)                                   |    |
| YES            | 30 (20.00%)  | 11 (14.29%)                                   | 19 (26.03%)                                   |    |
| Ranson score   |              |                                               |                                               | 0.396|
| < 3            | 130 (86.67%) | 69 (89.61%)                                   | 61 (83.56%)                                   |    |
| ≥ 3            | 20 (13.33%)  | 8 (10.39%)                                    | 12 (16.44%)                                   |    |
| APACHE II      | 7.00 (5.00–9.00) | 7.00 (5.00–9.00) | 8.00 (6.00–10.00) | 0.036|
| Treatment      |              |                                               |                                               |    |
| Insulin        | 101 (67.33%) | 51 (66.23%)                                   | 50 (68.49%)                                   | 0.904|
| Heparin        | 84 (56.00%)  | 43 (55.84%)                                   | 41 (56.16%)                                   | 1   |

BMI: body mass index; TG: triglyceride; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Ca: calcium.

Baseline Characteristics Of Total Cholesterol Subgroup Of Patients

As shown in Table 1, patients were categorized into 2 groups based on a TC level of 12.4 mmol/l. patients in the HTC group were older (p = 0.047) and lower proportion of male (P = 0.049). In terms of disease severity assessment, patients in the HTC group had more patients with Balthazar CT grade ≥ D (p < 0.001) and higher APACHE II score (p = 0.036). However, there was no significant difference in BMI, proportion of diabetes, HDL-C concentration, calcium level, blood amylase/lipase level and organ dysfunction between the two groups.

Effects Of Plasmapheresis On Primary Outcomes By Tc Categories

There was significant difference of PP’ curative effect between HTC and LTC groups in the reduction of TG below 500 mg/dl within 48 hours (Table 2). In patients with TC levels higher than 12.4 mmol/l, PP therapy decreased TGs more effectively (OR: 5.17; 95% CI: 1.88–14.19, p = 0.001); however, in patients with lower TC levels, there was no significant difference in the rate of the primary outcome (p = 0.164). After adjusting for age, sex, Balthazar CT grade and APACHE II score, the outcome remained consistent (p = 0.002 for HTC group and p = 0.353 for LTC group). Furthermore, the time course of the lowering of
TGs within 72 hours of admission categorized by TC-level groups is depicted in Fig. 1. There was no significant interaction effect between time and the treatment group (p = 0.459 for interaction) in the LTC group. However, we did find a significant association between rapidly reduction of TGs and PP therapy (p < 0.001 for interaction) in the HTC group.

Table 2
Effects of Plasmapheresis on primary outcomes by TC categories

| TC, mmol/L       | Crude OR (95%CI) | P value | Multivariable adjusted a OR (95%CI) | P     |
|------------------|------------------|---------|------------------------------------|-------|
| ≤ 12.40 (n = 77) | 2.62 (0.67–10.20)| 0.164   | 2.05 (0.45–9.40)                   | 0.353 |
| > 12.40 (n = 73) | 5.17 (1.88–14.19)| 0.001   | 5.47 (1.84–16.25)                  | 0.002 |

TC: total cholesterol

※: TG ≤ 500 mg/dl within 48 hours

a: adjusted for age, sex, Balthazar CT grade and APACHE II score.

Clinical outcomes of patients by TC categories and treatment group

The influence of PP to patients’ clinical outcome may be modified by TC levels. Accordingly, patients were divided into four groups based on their TC levels and whether they had been treated with PP. As shown in Table 3, 61 patients were classified into group 1 (LTC + non-PP), 16 into group 2 (LTC + PP), 43 into group 3 (HTC + non-PP), and 30 into group 4 (HTC + PP). Patients in group 2 and group 4 had higher effective rate in reducing TGs. Compared the group 1 and group 3, non-PP therapy seems less effective in reducing TGs when TC level more than 12.40 mmol/L. Patients from groups 2 and 4 had longer hospital stays and higher hospital costs. All deaths occurred in groups 3 and group 4. The 90-day mortality rates of group 3 and group 4 were 2.33% and 10.00%, respectively.
Table 3
Clinical outcomes of patients by TC categories and treatment group

|                  | Group 1                  | Group 2                  | Group 3                  | Group 4                  | P     |
|------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------|
| TC ≤ 12.40 mmol/L + non PP (n = 61) |                          |                          |                          |                          |       |
| TG ≤ 500 mg/dl within 48 hours          | 38 (62.30%)#             | 13 (81.25%)‡              | 12 (27.91%)#‡ξ           | 20 (66.67%)ξ             | < 0.001|
| Hospital stay, days                      | 8.00 (6.00–9.00)†        | 16.00 (10.00–21.50)‡      | 10.00 (7.00–12.50)‡      | 11.00 (8.25–16.75)†      | < 0.001|
| Hospital costs, Yuan in thousand          | 10.92 (8.69–14.37)‡      | 52.55 (30.89–91.59)‡      | 14.75 (12.01–21.34)‡ξ    | 40.17 (35.30–55.88)†ξ    | < 0.001|
| 28-day mortality                           | 0 (0%)                   | 0 (0%)                   | 1 (2.33%)                | 1 (3.33%)                | 0.438  |
| 90-day mortality                           | 0 (0%)†                  | 0 (0%)                   | 1 (2.33%)                | 3 (10.00%)†              | 0.039  |

*: p < 0.05 for groups 1 vs. 2
#: p < 0.05 for groups 1 vs. 3
†: p < 0.05 for groups 1 vs. 4
‡: p < 0.05 for groups 2 vs. 3
¶: p < 0.05 for groups 2 vs. 4
ξ: p < 0.05 for groups 3 vs. 4

TC was associated with baseline TG and the relationship of TC and the TG-lowering effect of 2 therapy groups might also be mediated by baseline TG. Furthermore, patients were categorized into high triglyceride (HTG) /low triglyceride (LTG) groups based on a TG level of 1760 mg/dl (median value of TG). We used a classification definition which incorporated TG and TC to divide the patients into LTC + LTG/LTC + HTG/HTC + LTG/HTC + HTG groups. To explore the curative effect of PP, we itemized each group into subgroups of PP and non-PP. As depicted in Fig. 2, PP was shown to be more effective in reducing TGs below 500 mg/dl in the LTC + LTG and HTC + HTG groups within 48 hours. PP also seemed to be effective in the HTC + LTG group, although the p value exceeded 0.05. Intriguingly, its seems that patients in LTC/HTG group showed a better reduction of TG by non-PP therapy.

Discussion
In patients with HLAP, different TC level can result in different therapeutic effects of TG-lowering treatments in clinical application. To our knowledge, this is the first study to explore the association between TC levels and PP therapy among patients with HLAP.

Previous studies have shown that a higher level of TGs is accompanied by a higher probability of suffering from AP, more severe disease, and organ dysfunction[17, 20, 21]. Reducing TG levels as soon as possible is an important strategy for the treatment of HLAP. PP has traditionally been considered an alternative to TG clearance. the American Society for Apheresis (ASFA) suggests Grade 2C for PP as an indication for HLAP[22].

Many studies have shown that PP should be performed as early as possible in patients with HLAP[8, 23]. However, a few previous studies with limited sample sizes have shown that PP did not more effectively reduce TG concentrations and conservative treatment is effective and safe without PP [12, 24]. Such controversies may be related to the surrogate endpoint, instead of clinical outcomes to evaluate the effect of TG-lowering therapy, in which variability and inconsistency with clinical outcome have been shown.

Until now, what kind of HLAP patients more suitable for PP remains unclear[9]. Early identification of patients suitable for PP is of significant clinical importance [25]. Our study has a relatively large sample size with long time span, which enhances the reliability of the results. In our study, we found that the plasma TC concentration in most patients far exceeded the ‘high’ limit recommended by the NHLBI. After further grouping by TC concentration, PP showed more efficacy in reducing TGs in the HTC group but not in LTC group. Further considering the impact of baseline TG, patients with HTC and HTC were most suitable for PP treatment, while patients with HTG and LTC were least suitable. Lipid metabolism is dramatically complex and varies from person to person. Common risk factors, such as age, gender, insulin/heparin treatment, Balthazar CT grade and severity of illness, are known to interfere with TG-lowering treatment[26]. We have adjusted these factors and found that TC remained have an independent effect on TG-lowering therapy and the outcomes.

In addition, primary genetic variations among patients are also an important factor of affecting lipid metabolism[27, 28]. However, it is time-consuming and expensive to perform genetic screening. In contrast, measuring blood biomarkers such as TC level was practical, easy to operate, and economical to predict a patient’s response to TG-lowering therapy.

Bile acids are synthesized from TC in the liver and play an important role in the solubilization of lipids in the intestine by acting as biological detergents. Bile acids also affect the absorption of dietary fat, and perturbing bile acid production results in reduced lipid absorption[29]. On the other hand, many enzymes or receptors, such as glycerol-3-phosphate acyltransferase 3, acyl-CoA synthase 5, liver X receptors and farnesoid X receptor, are involved in the metabolism of TC and TGs, and there is a mutual feedback regulatory effect[30]. The mutual feedback regulatory mechanism between TC and TGs has not been fully understood, and further research is needed.
Previous studies have shown that the release of systemic inflammatory factors is involved in the occurrence and development of AP[31, 32]. HTC not only leads to a severe inflammatory state, it was an independent risk factor for SAP development [33, 34]. There is evidence that HTC can lead macrophages and other immune cells to release a large amount of inflammatory factors by enhancing Toll-like receptor (TLR) signaling[35]. The amplification of the inflammatory process can lead to pancreatitis-associated organ injury[36, 37]. Furthermore, through the nuclear transcription factor kappa-B (NF-kB) signaling pathway, HTC can also increase the release of oxygen free radicals, regulate disorders of lipid peroxidation, damage endothelial cells, and cause further organ dysfunction[38–40]. Moreover, many animal experiments have shown that HTC can also produce more inflammatory cells by promoting the maturation of the bone marrow and spleen[41]. PP can rapidly remove a variety of inflammatory factors and antibodies, reduce systemic inflammatory reactions and alleviate organ function damage[42, 43]. Patients with elevated TC level may benefit from PP therapy. However, it cannot be fooled that PP has the disadvantages of higher costs, longer hospital stays, and more complicated operations.

Our study has several limitations. Firstly, it was a retrospective observational study, the PP group included more severe patients. However, after adjustment for conventional confounding factors, the results remained consistent. Secondly, no gene analysis was performed to determine whether the clinical effects of PP were related to the patient's genotype. Thirdly, cytokine levels were not detected, so the relationship between the efficiency of PP in removing inflammatory cytokines and prognosis was unclear. Rigorous foresight is necessary to further explore the correlation between TC and TG-lowering therapy with controlled studies.

Conclusions

Baseline TC level may predict the effect of conservative treatment or PP therapy on TG-lowering in HLAP patients. TC may also serve as an adjunctive biomarker for clinical selection of patients more suitable for PP.

Abbreviations

PP
plasmapheresis
HLAP
hypertriglyceridemic acute pancreatitis
TC
total cholesterol
AP
acute pancreatitis
TG
triglyceride
HTG
Declarations

Ethics approval and consent to participate

The protocol of this retrospective study was approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding:

No
Authors' contributions:

ZC, data interpretation and evaluation, manuscript writing.

XH, data collection, analysis and interpretation.

NH, data collection and analysis.

YG, data collection.

JC, data collection.

YN, data collection.

MZ, study concept and design, manuscript writing and revision.

Acknowledgements

Not applicable

References

1. Singla A, Csikesz NG, Simons JP, Li YF, Ng SC, Tseng JF, Shah SA. National hospital volume in acute pancreatitis: analysis of the nationwide inpatient sample 1998–2006. HPB (Oxford). 2009;11:391–7.

2. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. AM J GASTROENTEROL. 2009;104:984–91.

3. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS. Classification of acute pancreatitis—2012: revision of the atlanta classification and definitions by international consensus. GUT. 2013;62:102–11.

4. Tai WP, Lin XC, Liu H, Wang CH, Wu J, Zhang NW, Chen W. A retrospective research of the characteristic of hypertriglyceridemic pancreatitis in beijing, china. Gastroenterol Res Pract. 2016;2016:6263095.

5. Deng LH, Xue P, Xia Q, Yang XN, Wan MH. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008;14:4558–61.

6. Coskun A, Erkan N, Yakan S, Yildirim M, Carti E, Ucar D, Oymaci E. Treatment of hypertriglyceridemia-induced acute pancreatitis with insulin. Prz Gastroenterol. 2015;10:18–22.

7. Kadikoylu G, Yukselen V, Yavaşoğlu I, Coskun A, Karaoglu AO, Bolaman Z. Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia. TRANSFUS APHER SCI. 2010;43:285–9.

8. Stefanutti C, Labbadia G, Morozzi C. Severe hypertriglyceridemia-related acute pancreatitis. THER APHER DIAL. 2013;17:130–7.
9. Click B, Ketchum AM, Turner R, Whitcomb DC, Papachristou GI, Yadav D. The role of apheresis in hypertriglyceridemia-induced acute pancreatitis: a systematic review. PANCREATOLOGY. 2015;15:313–20.

10. Gubensek J, Buturovic-Ponikvar J, Romozi K, Ponikvar R. Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange: an observational cohort study. PLOS ONE. 2014;9:e102748.

11. Miyamoto K, Horibe M, Sanui M, Sasaki M, Sugiyama D, Kato S, Yamashita T, Goto T, Iwasaki E, Shirai K, Oe K, Sawano H, Oda T, Yasuda H, Ogura Y, Hirose K, Kitamura K, Chiba N, Ozaki T, Oshima T, Yamamoto T, Nagata K, Mine T, Saito K, Sekino M, Furuya T, Matsuda N, Hayakawa M, Kanai T, Mayumi T. Plasmapheresis therapy has no triglyceride-lowering effect in patients with hypertriglyceridemic pancreatitis. Intensive Care Med. 2017;43:949–51.

12. Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (shtg): the role of apheresis. Clin Res Cardiol Suppl. 2012;7:31–5.

13. Zhou CL, Zhang CH, Zhao XY, Chen SH, Liang HJ, Hu CL, Chen NW. Early prediction of persistent organ failure by serum apolipoprotein a-i and high-density lipoprotein cholesterol in patients with acute pancreatitis. CLIN CHIM ACTA. 2018;476:139–45.

14. Zhang Y, Guo F, Li S, Wang F, Meng Z, Zhao J, Liu Z, Wang B, Fan P, Wang C, Wu H. Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis. Sci Rep. 2017;7:8064.

15. Hong W, Lin S, Zippi M, Geng W, Stock S, Zimmer V, Xu C, Zhou M. High-density lipoprotein cholesterol, blood urea nitrogen, and serum creatinine can predict severe acute pancreatitis. BIOMED RES INT. 2017;2017:1648385.

16. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS. Classification of acute pancreatitis–2012: revision of the atlanta classification and definitions by international consensus. GUT. 2013;62:102–11.

17. Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. EUR J INTERN MED. 2014;25:689–94.

18. Chatzicostas C, Roussomoustakaki M, Vardas E, Romanos J, Kouroumalis EA. Balthazar computed tomography severity index is superior to ranson criteria and apache ii and iii scoring systems in predicting acute pancreatitis outcome. J CLIN GASTROENTEROL. 2003;36:253–60.

19. Executive summary of the third report of the national cholesterol education. program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA. 2001;285:2486–97.

20. Vipperla K, Somerville C, Furlan A, Koutroumpakis E, Saul M, Chennat J, Rabinovitz M, Whitcomb DC, Slivka A, Papachristou GI, Yadav D. Clinical profile and natural course in a large cohort of patients with hypertriglyceridemia and pancreatitis. J CLIN GASTROENTEROL. 2017;51:77–85.

21. Wang SH, Chou YC, Shangkuan WC, Wei KY, Pan YH, Lin HC. Relationship between plasma triglyceride level and severity of hypertriglyceridemic pancreatitis. PLOS ONE. 2016;11:e163984.
22. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the american society for apheresis: the seventh special issue. J Clin Apher. 2016;31:149–62.

23. Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10:2272–4.

24. Berberich AJ, Ziada A, Zou GY, Hegele RA. Conservative management in hypertriglyceridemia-associated pancreatitis. J INTERN MED. 2019;286:644–50.

25. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. GUT. 2008;57:1698–703.

26. Jain P, Rai RR, Udawat H, Nijhawan S, Mathur A. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol. 2007;13:2642–3.

27. Rodrigues R, Artieda M, Tejedor D, Martinez A, Konstantinova P, Petry H, Meyer C, Corzo D, Sundgreen C, Klor HU, Gouni-Berthold I, Westphal S, Steinhagen-Thiessen E, Julius U, Winkler K, Stroes E, Vogt A, Hardt P, Prophet H, Otte B, Nordestgaard BG, Deeb SS, Brunzell JD. Pathogenic classification of LPL gene variants reported to be associated with LPL deficiency. J CLIN LIPIDOL. 2016;10:394–409.

28. Chokshi N, Blumenschein SD, Ahmad Z, Garg A. Genotype-phenotype relationships in patients with type I hyperlipoproteinemia. J CLIN LIPIDOL. 2014;8:287–95.

29. Paalvast Y, de Boer JF, Groen AK. Developments in intestinal cholesterol transport and triglyceride absorption. CURR OPIN LIPIDOL. 2017;28:248–54.

30. Kalaany NY, Mangelsdorf DJ. Lxrs and fxr: the yin and yang of cholesterol and fat metabolism. ANNU REV PHYSIOL. 2006;68:159–91.

31. Leung PS, Chan YC. Role of oxidative stress in pancreatic inflammation. Antioxid Redox Signal. 2009;11:135–65.

32. Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, Lopez-Rodas G, Sastre J. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. Curr Pharm Des. 2009;15:3027–42.

33. Nawaz H, Koutroumpakis E, Easler J, Slivka A, Whitcomb DC, Singh VP, Yadav D, Papachristou GI. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. AM J GASTROENTEROL. 2015;110:1497–503.

34. Hong W, Zimmer V, Basharat Z, Zippi M, Stock S, Geng W, Bao X, Dong J, Pan J, Zhou M. Association of total cholesterol with severe acute pancreatitis: a U-shaped relationship. CLIN NUTR. 2020;39:250–7.

35. Triantaflou M, Miyake K, Golenbock DT, Triantaflou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J CELL SCI. 2002;115:2603–11.

36. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. NAT REV IMMUNOL. 2015;15:104–16.
37. Pastor CM, Pugin J, Kwak B, Chanson M, Mach F, Hadengue A, Frossard JL. Role of toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. CRIT CARE MED. 2004;32:1759–63.

38. Escobar J, Pereda J, Arduini A, Sandoval J, Sabater L, Aparisi L, Lopez-Rodas G, Sastre J. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. Curr Pharm Des. 2009;15:3027–42.

39. Hermida N, Balligand JL. Low-density lipoprotein-cholesterol-induced endothelial dysfunction and oxidative stress: the role of statins. Antioxid Redox Signal. 2014;20:1216–37.

40. Escobar J, Pereda J, Lopez-Rodas G, Sastre J. Redox signaling and histone acetylation in acute pancreatitis. Free Radic Biol Med. 2012;52:819–37.

41. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR. Atp-binding cassette transporters and hdl suppress hematopoietic stem cell proliferation. SCIENCE. 2010;328:1689–93.

42. Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. AUTOIMMUN REV. 2016;15:38–49.

43. Hatano Y, Katagiri K, Arakawa S, Umeki T, Takayasu S, Fujiwara S. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol. 2003;148:573–9.

Figures
Figure 1

Time course of the serum triglyceride concentration changes within 72 hours after admission by total cholesterol levels. a: Time course of triglyceride changes in the low total cholesterol group. Compared with the effects observed in the non-plasmapheresis group, plasmapheresis did not reduce triglyceride more effectively (p=0.459). b: Time course of triglyceride changes in the high total cholesterol group.
Compared with the effects observed in the non-plasmapheresis group, plasmapheresis reduced the triglyceride concentration more effectively (P<0.001).

Figure 2

Effect of plasmapheresis and non-plasmapheresis in different triglyceride and total cholesterol combination groups. TC, total cholesterol; TG, triglyceride.